Li Kang Biomedical Co., Ltd. Reports Earnings Results for the Third Quarter Ended September 30, 2019
November 06, 2019 at 04:50 pm
Share
Li Kang Biomedical Co., Ltd. announced earnings results for the third quarter ended September 30, 2019. For the third quarter, the company announced total revenue was TWD 98.391 million compared to TWD 107.656 million a year ago. Operating income was TWD 13.677 million compared to TWD 16.150 million a year ago. Net income was TWD 11.153 million compared to TWD 12.771 million a year ago. Basic earnings per share was TWD 0.5 compared to TWD 0.58 a year ago. Diluted earnings per share was TWD 0.5 compared to TWD 0.57 a year ago. For the nine months, total revenue was TWD 345.096 million compared to TWD 372.971 million a year ago. Operating income was TWD 59.431 million compared to TWD 68.052 million a year ago. Net income was TWD 49.416 million compared to TWD 56.167 million a year ago. Basic earnings per share was TWD 2.23 compared to TWD 2.53 a year ago. Diluted earnings per share was TWD 2.21 compared to TWD 2.52 a year ago.
Li Kang Biomedical Co., Ltd. formerly BAFO TECHNOLOGIES CORP., is engaged in the manufacture and sale of computer, communication and consumer (3C) product cables and circumscribed computer peripheral products, as well as communication products. The Company offers unshielded twisted pair (UTP) cables, monitor cables, small computer system interface (SCSI) cables, universal serial bus (USB) cables, wireless hopping/mesh access points, wireless modules, and wireless vehicle communication systems, among others. The Company distributes its products within the domestic market and to overseas markets, including Europe, the Americas and the rest of Asia.
LI KANG BIOMEDICAL CO., LTD. 
